ArticleJournal of ophthalmology2017
Changes in Glaucoma Medication during the Past Eight Years and Future Directions in Japan Based on an Insurance Medical Claim Database.
Article in Journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study.Japanese journal of ophthalmology · 2021Trial
- Investigation of visual and physical factors associated with inadequate instillation of eyedrops among patients with glaucoma.PloS one · 2021Trial
- Trends in First-Line Glaucoma Treatment from 2013 to 2024: A Multi-institutional and Multinational Cohort Study.Ophthalmology and therapy · 2026Article
- Forecasting trends in glaucoma medication reimbursees in Finland: updated system dynamics model to 2070.BMJ open ophthalmology · 2025Article
- Users of reimbursed glaucoma medications in Finland in 1986-2023: A nationwide study.Acta ophthalmologica · 2025Article
- Article
- Improvement of corneal epithelial damage after switching from the concomitant use of brinzolamide and brimonidine to a brinzolamide/brimonidine fixed-dose combination.Japanese journal of ophthalmology · 2024Article
- Prescribing trends of glaucoma medication in Korea from 2007 to 2020: A nationwide population-based study.PloS one · 2024Article
- Patient journey through cases of depression from claims database using machine learning algorithms.PloS one · 2021Article
- Efficacy and safety of timolol-dorzolamide fixed-combination three times a day versus two times a day in newly diagnosed open-angle glaucoma.Journal of drug assessment · 2021Article
- The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 (Diagnostics (Basel, Switzerland) · 2020Article
- Article
- Wide Variation of Squeezing Force and Dispensing Time Interval among Eyedropper Bottles.Journal of ophthalmology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate changes in the status of glaucoma care between 2006 and 2013 and to predict future directions of glaucoma care in Japan. SUBJECTS AND
methodsJapanese subjects registered in the largest national insurance claim database in Japan from 2006 to 2013 were analyzed. Estimations of the number of glaucoma patients during the past eight years and of the number of future patients were calculated. Changes in prescription trends among the same patients in the three-year period after initiating antiglaucoma medication were also investigated.
resultsThere was a total of 3,016,000 subjects in the database. The proportion of glaucoma patients increased consistently from 2.5% in 2006 to 4.5% in 2013. This trend was predicted to continue until 2025, followed by a constant decrease with age. The most frequently prescribed antiglaucoma medications were prostaglandin analogues (PGs); however, in recent years, fixed combination therapy has emerged as a major treatment. Among 2856 newly diagnosed glaucoma patients; 94.7% of the patients initially received a single medication, but 25% of the patients received additional medications within 3 years.
conclusionsThe prevalence of glaucoma patients has significantly increased during the past eight years. The number of antiglaucoma medications continuously increased during the treatment period.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.